Introduction
Insulin downregulates catabolic and activates anabolic pathways, suppresses apoptosis and promotes mitosis by activating a homodimeric receptor, tyrosine kinase [
1,
2]. Human loss-of-function mutations in the
INSR gene, which encodes the insulin receptor (INSR), were first reported in 1988 [
3,
4]. Since then, more than 100 alleles causing severe insulin resistance have been described [
5]. Bi-allelic
INSR mutations produce extreme insulin resistance, clinically described as Donohue or Rabson–Mendenhall syndromes (OMIM #246200 or #262190). These also feature impaired linear growth and soft tissue overgrowth, with demise usually in the first 3 years of life in Donohue syndrome.
Some
INSR mutations impair receptor processing and cell surface expression. Many mutations, however, are well expressed, but exhibit impaired insulin binding, impaired signal transduction, perturbed recycling kinetics or a combination of these [
6]. Proof that the signalling defect of such mutant receptors might be circumvented by binding anti-receptor antibodies was provided for two mutations, one in a cell culture model and one as solubilised receptor [
7,
8].
Therapeutic antibodies are now well established both in cancer, often blocking receptor signalling [
9], and increasingly for non-cancer indications [
10]. Interest in biological therapies targeting the INSR has recently rekindled, with inhibitory antibodies in Phase 1 human trials [
11] and stimulatory antibodies shown to ameliorate diabetes in rodents [
12‐
14] and primates [
15]. Given the high clinical need in recessive insulin receptoropathy, we assessed the effect of monoclonal anti-INSR antibodies [
16‐
20] on a series of disease-causing mutant INSRs.
Discussion
Recessive insulin receptoropathies feature failure to thrive, extreme metabolic derangement, childhood mortality and poor response to therapy. Longitudinal studies suggest a steep relationship between residual INSR function and clinical outcome: loss of 50% INSR function, as in the parents of infants with Donohue syndrome, does not produce insulin resistance in lean people. Heterozygous dominant negative mutations produce severe insulin resistance, diagnosed peripubertally in girls and later in men, and reduce receptor function to 25% or less of WT. The severe recessive receptoropathies that this study focuses on confer greater loss of function. However, even with 0–25% residual function, a range of phenotypes is seen, with complete loss of function producing Donohue syndrome and lethality in infancy, but less extreme loss of function producing Rabson–Mendenhall syndrome, with survival to the second or third decade. These observations suggest that even modest improvements in receptor signalling in recessive disease may have decisive clinical benefit.
Many pathogenic
INSR mutations are known, including more than 100 missense mutations. A subset are expressed at the cell surface, but show impaired insulin binding, signal transduction or internalisation and recycling. This subset may be amenable to non-conventional activation by antibody. Proof of this principle came from demonstration that two bivalent antibodies stimulated kinase activity of a single solubilised mutant receptor (F382V [
7]), and, independently, that one bivalent antibody increased glycogen synthesis acting via a mutant receptor expressed in intact cells (S232L [
8]). We extend these findings with systematic characterisation of multiple receptor mutants and antibodies in two cellular systems, assaying physiologically important responses including adipocyte glucose uptake.
One of the mutants assessed, F248C, is novel. It lies close to the R252C mutant, which is expressed but exhibits impaired internalisation after insulin exposure [
33]. F248C shows minor reduction in cell surface expression, but insulin-stimulated receptor autophosphorylation and downstream signalling are severely impaired. Across known mutants, our data generally agree with prior studies. Assay of receptor autophosphorylation in CHO cells using immunocapture of myc-tagged receptor prior to immunoassay demonstrated signalling defects more clearly than phosphotyrosine immunoblotting in the 3T3-L1 overexpression system, likely reflecting the inherently greater dynamic range of immunoassay allied to use of a generic anti-phosphotyrosine antibody.
We confirmed that S323L and F382V receptors can be activated by antibodies and extended these observations to a wider range of mutants. Previous studies suggest that receptor activation by antibody depends on receptor cross-linking rather than reaction at specific epitopes [
19]. Consistent with this, two of the antibodies we employed, 83-7 and 83-14, are both effective despite recognising different epitopes and having different effects on insulin binding. Antibodies 18-44 and 18-146 consistently elicited much smaller responses, although 18-44 has previously been found to exert insulin-like activity on primary human adipocytes [
20]. Differences among antibodies are likely to reflect differences of affinity and/or steric constraints on cross-linking receptors.
The mutants showing the largest antibody response were S323L and D707A, both being activated by antibodies similarly to WT receptor, and to a greater extent than by insulin. Such mutants with ‘pure’ insulin-binding defects are particularly attractive therapeutic targets. Other mutants studied in both cell systems (P193L, F248C, R252C and F382V) showed some activation of Akt, GSK3, AS160 and glucose uptake by antibodies. In these cases, responses were less than for WT receptor or those induced by insulin. Testing the therapeutic potential of antibodies against such mutants is warranted in vivo, where antibody signalling may be prolonged compared with insulin signalling because of slower receptor internalisation. Indeed, a previously studied anti-INSR antibody showed markedly greater hypoglycaemic effects in vivo in WT animals than had been apparent in cell culture models [
13].
Antibodies would be a particularly appealing therapeutic proposition were they to exhibit synergy with insulin in receptor stimulation, amplifying insulin action rather than simply imposing a tonic signal. The current studies have not addressed this in detail, although suggestive evidence for synergic stimulation of WT receptor and some mutant receptors is seen. This was not mirrored by detectable synergistic activation of downstream signalling or metabolic endpoints, possibly because maximal downstream signalling requires only submaximal receptor autophosphorylation. It remains possible that insulin–antibody synergy does exist but was obscured under the conditions of the experiments undertaken, which pragmatically employed relatively high concentrations of insulin and antibody.
Early cellular studies of antibody-induced INSR activation were interpreted as suggesting that antibodies elicit greater downstream responses than expected from low levels of receptor autophosphorylation [
16,
34‐
36]. These observations were later argued to have a methodological basis, hinging on lower sensitivity in detecting tyrosine phosphorylation than downstream signalling [
37,
38]. This is, in part, because signal amplification is an inherent property of signal transduction cascades. Our observation of apparent ‘escape’ from signalling inhibition in the face of efficient
Insr knockdown in 3T3-L1 adipocytes supports this contention, as activation of residual receptors is undetectable directly but is observable downstream, owing to signal amplification.
Importantly, receptor activation by antibodies leads to selective Akt phosphorylation, which is critical for metabolic actions of insulin, with little or no ERK phosphorylation. As activation of the RAS/RAF/MEK/ERK pathway is mitogenic, this is an encouraging property of antibodies for translational purposes, suggesting that they may exert metabolic benefits without undue mitogenic activity. Similar dissociation between activation of Akt and ERK has also been observed following INSR activation by the peptide ligand S597 [
39] and in previous studies with anti-receptor antibodies [
40]. The mechanism underlying such biased agonism is poorly understood, although IRS proteins may be preferentially phosphorylated by plasma membrane-associated receptor [
33,
41], whereas receptor internalisation is required for full ERK activation [
33,
42].
We studied only a limited number of insulin and antibody concentrations. While these were selected with reference to prior studies and observed blood insulin concentrations in insulin receptoropathy, the conditions we describe may not be most relevant in vivo, where insulin and antibody concentrations in the interstitial space of target tissues may be variable and different. Moreover, receptor overexpression may have partially overcome receptor dysfunction and made beneficial effects of antibody more difficult to observe. Finally, in the paradigm of acute antibody stimulation with static signalling endpoints, issues such as the potential of long-term antibody treatment to downregulate receptors, and the effect of antibodies on receptor recycling kinetics in vivo have not been addressed. This is likely to be particularly important for the subset of mutants (e.g. I119M, K460E) where acute insulin stimulations studies are normal, as in this and other reports, but which confer extreme insulin resistance in vivo.
Acknowledgements
We thank C. Gewert and D. Newby (Institute of Metabolic Science, University of Cambridge, Cambridge, UK) for technical support. Some of the data were presented as abstracts at the Diabetes UK Professional Conference in London, UK, 11–13 March 2015 and Manchester, UK, 7–10 March 2017, and the International Symposium on Insulin Receptor and Insulin Action 2017, Nice, France, 20–22 April 2017.